At the news
? BEARISHIMPACT 7/10 8-K filed Apr 17, 2026 at 08:06 ET
Trevi Therapeutics priced a $150 million follow-on offering just one day after reporting earnings, raising concerns about capital needs despite improved cash runway. The company provided updates on its Phase 3 trials for Haduvio, with topline results expected in 2027-2028.
- Priced $150 million follow-on offering at $13.00/share, one day after earnings report
- Cash runway extended to 2029 from $171.8 million as of March 31, 2026
- Net proceeds estimated at $141.1 million after fees
- Company maintains it will fund development through FDA approval for IPF indication
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access